By Fineline Cube Fujian Haixi Pharmaceuticals Co., Ltd. (HKG: 2637) announced that the Investigational New Drug (IND) application for HX9428, its independently developed innovative drug candidate for the treatment of neovascular age-related macular degeneration (nAMD), has been approved by the US Food and Drug Administration (FDA) to proceed with Phase 2 clinical trials. The company has also initiated a Phase 2 clinical study of HX9428 for nAMD in China.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | US FDA |
| Approval Type | IND clearance for Phase 2 clinical trials |
| Product | HX9428 (oral innovative drug candidate) |
| Indication | Neovascular age-related macular degeneration (nAMD) |
| Additional Indications | Fundus neovascularization-related disorders |
| Development Status | Phase 2 trials initiated in both US and China |
Drug Profile & Therapeutic Innovation
- Administration Route: Oral (first-in-class potential for nAMD)
- Target Population: Patients with nAMD and related fundus neovascularization disorders
- Key Innovation: Addresses critical unmet need by providing non-invasive alternative to current standard of care
- Current Standard: Intravitreal injections requiring frequent ophthalmologist visits and carrying procedural risks
- Patient Benefit: Enhanced convenience, improved compliance, and reduced treatment burden
Market Opportunity & Competitive Landscape
- nAMD Prevalence: Affects approximately 1.6 million Americans aged 50+; global market projected to reach $15 billion by 2030
- Treatment Limitations: Current anti-VEGF intravitreal injections require monthly or bimonthly administration
- Compliance Challenges: Up to 50% of patients receive fewer injections than recommended due to treatment burden
- Competitive Advantage: HX9428 represents one of the few oral candidates in late-stage development for nAMD
- Dual-Market Strategy: Simultaneous US and China clinical development accelerates global commercial potential
Development Strategy & Timeline
- Phase 2 Design: Parallel studies in US and China to generate robust efficacy and safety data
- Primary Endpoints: Likely to include visual acuity improvement, reduction in retinal thickness, and neovascularization activity
- Regulatory Pathway: Potential for breakthrough therapy designation if early efficacy signals are strong
- Next Milestones: Phase 2 completion expected 2027–2028, with potential Phase 3 initiation thereafter
Strategic Implications for Haixi Pharma
- Pipeline Diversification: Expands beyond traditional therapeutic areas into high-value ophthalmology market
- Global Ambition: FDA approval demonstrates capability to meet international regulatory standards
- Innovation Validation: Independently developed candidate showcases internal R&D capabilities
- Partnership Potential: Strong Phase 2 data could attract global pharmaceutical partners for commercialization
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical trial progress, regulatory approvals, and commercial potential. Actual outcomes may differ due to risks including clinical trial results, regulatory decisions, competitive dynamics, and market acceptance.-Fineline Info & Tech